Using our recently developed antigenic orthotopic lung cancer model (50), we revealed that DRP-104 not only is effective in targeting Keap1 mutant lung tumors but also, in combination with checkpoint blockade DRP-104, led to significantly enhanced survival of mice compared to monotherapy. This evidence concerns the gene KEAP1 and lung cancer.